S&P 500   3,658.04 (-0.12%)
DOW   29,777.31 (-0.16%)
QQQ   303.20 (-0.09%)
AAPL   123.07 (+0.29%)
MSFT   214.45 (-0.81%)
FB   287.80 (+0.44%)
GOOGL   1,827.00 (+1.76%)
AMZN   3,206.72 (-0.41%)
TSLA   560.27 (-4.19%)
NVDA   541.78 (+1.15%)
BABA   261.58 (-0.92%)
CGC   28.39 (+6.53%)
GE   10.35 (+1.97%)
MU   68.75 (+2.49%)
AMD   93.59 (+1.04%)
T   28.94 (+0.24%)
NIO   47.57 (+4.87%)
F   9.17 (-0.76%)
ACB   10.99 (+12.72%)
NFLX   503.01 (-0.31%)
BA   221.32 (+3.90%)
GILD   61.16 (+0.07%)
DIS   152.41 (+1.99%)
S&P 500   3,658.04 (-0.12%)
DOW   29,777.31 (-0.16%)
QQQ   303.20 (-0.09%)
AAPL   123.07 (+0.29%)
MSFT   214.45 (-0.81%)
FB   287.80 (+0.44%)
GOOGL   1,827.00 (+1.76%)
AMZN   3,206.72 (-0.41%)
TSLA   560.27 (-4.19%)
NVDA   541.78 (+1.15%)
BABA   261.58 (-0.92%)
CGC   28.39 (+6.53%)
GE   10.35 (+1.97%)
MU   68.75 (+2.49%)
AMD   93.59 (+1.04%)
T   28.94 (+0.24%)
NIO   47.57 (+4.87%)
F   9.17 (-0.76%)
ACB   10.99 (+12.72%)
NFLX   503.01 (-0.31%)
BA   221.32 (+3.90%)
GILD   61.16 (+0.07%)
DIS   152.41 (+1.99%)
S&P 500   3,658.04 (-0.12%)
DOW   29,777.31 (-0.16%)
QQQ   303.20 (-0.09%)
AAPL   123.07 (+0.29%)
MSFT   214.45 (-0.81%)
FB   287.80 (+0.44%)
GOOGL   1,827.00 (+1.76%)
AMZN   3,206.72 (-0.41%)
TSLA   560.27 (-4.19%)
NVDA   541.78 (+1.15%)
BABA   261.58 (-0.92%)
CGC   28.39 (+6.53%)
GE   10.35 (+1.97%)
MU   68.75 (+2.49%)
AMD   93.59 (+1.04%)
T   28.94 (+0.24%)
NIO   47.57 (+4.87%)
F   9.17 (-0.76%)
ACB   10.99 (+12.72%)
NFLX   503.01 (-0.31%)
BA   221.32 (+3.90%)
GILD   61.16 (+0.07%)
DIS   152.41 (+1.99%)
S&P 500   3,658.04 (-0.12%)
DOW   29,777.31 (-0.16%)
QQQ   303.20 (-0.09%)
AAPL   123.07 (+0.29%)
MSFT   214.45 (-0.81%)
FB   287.80 (+0.44%)
GOOGL   1,827.00 (+1.76%)
AMZN   3,206.72 (-0.41%)
TSLA   560.27 (-4.19%)
NVDA   541.78 (+1.15%)
BABA   261.58 (-0.92%)
CGC   28.39 (+6.53%)
GE   10.35 (+1.97%)
MU   68.75 (+2.49%)
AMD   93.59 (+1.04%)
T   28.94 (+0.24%)
NIO   47.57 (+4.87%)
F   9.17 (-0.76%)
ACB   10.99 (+12.72%)
NFLX   503.01 (-0.31%)
BA   221.32 (+3.90%)
GILD   61.16 (+0.07%)
DIS   152.41 (+1.99%)
Log in
NYSEAMERICAN:IBIO

iBio Stock Forecast, Price & News

$1.62
+0.18 (+12.07 %)
(As of 12/2/2020 02:02 PM ET)
Add
Compare
Today's Range
$1.53
Now: $1.63▼
$1.75
50-Day Range N/A
52-Week Range
$0.11
Now: $1.63▼
$7.45
Volume686,322 shs
Average Volume21.77 million shs
Market Capitalization$295.93 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.34 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:IBIO
Previous SymbolNASDAQ:IBIO
CUSIPN/A
CIK1420720
Webwww.ibioinc.com
Phone+1-302-3550650
Employees43

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares182,108,000
Market Cap$295.93 million
Next Earnings Date2/12/2021 (Estimated)
OptionableNot Optionable
$1.62
+0.18 (+12.07 %)
(As of 12/2/2020 02:02 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











iBio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of iBio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for iBio or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than iBio?

Wall Street analysts have given iBio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but iBio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is iBio's next earnings date?

iBio is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for iBio.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) issued its earnings results on Monday, November, 16th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03.
View iBio's earnings history.

When did iBio's stock split? How did iBio's stock split work?

Shares of iBio reverse split on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

1 brokerages have issued twelve-month target prices for iBio's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate iBio's stock price to reach $2.00 in the next year. This suggests a possible upside of 26.6% from the stock's current price.
View analysts' price targets for iBio.

Are investors shorting iBio?

iBio saw a decrease in short interest in October. As of October 15th, there was short interest totaling 13,640,000 shares, a decrease of 16.9% from the September 30th total of 16,410,000 shares. Based on an average daily trading volume, of 20,830,000 shares, the days-to-cover ratio is presently 0.7 days.
View iBio's Short Interest.

Who are some of iBio's key competitors?

Some companies that are related to iBio include Aptose Biosciences (APS), PureTech Health (PRTC), SQZ Biotechnologies (SQZ), Spruce Biosciences (SPRB), Oxford Biomedica plc (OXB.L) (OXB), Oncorus (ONCR), SIGA Technologies (SIGA), Biotest Aktiengesellschaft (BIO.F) (BIO), Inventiva (IVA), CEL-SCI (CVM), Humanigen (HGEN), Altimmune (ALT), Altimmune (ALT), Pfenex (PFNX) and Novacyt S.A. (NCYT.L) (NCYT).
View all competitors.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

Who are iBio's key executives?

iBio's management team includes the following people:
  • Mr. Thomas F. Isett III, CEO & Chairman (Age 55, Pay $1.03M)
  • Mr. Robert L. Erwin, Pres (Age 67, Pay $291.75k)
  • Mr. Robert B. Kay, Interim Sec., Interim Treasurer & Director (Age 80, Pay $324.69k)
  • Mr. John Delta, Principal Accounting Officer & Principal Financial Officer (Age 58)
  • Dr. Renato Lobo, Chief Medical Officer
  • Dr. R. Barry Holtz, Pres of iBio CDMO
  • Carlos Picosse, Chief Exec. Officer of IBio Brazil

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.02%), State Street Corp (0.47%), Morgan Stanley (0.17%), Charles Schwab Investment Management Inc. (0.11%), AQR Capital Management LLC (0.09%) and Wells Fargo & Company MN (0.09%). Company insiders that own iBio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for iBio.

Which major investors are selling iBio stock?

IBIO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, and National Asset Management Inc.. Company insiders that have sold iBio company stock in the last year include Eastern Capital Ltd, James P Mullaney, and Robert L Erwin.
View insider buying and selling activity for iBio.

Which major investors are buying iBio stock?

IBIO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Morgan Stanley, AQR Capital Management LLC, Charles Schwab Investment Management Inc., LPL Financial LLC, Wells Fargo & Company MN, and Strategic Wealth Management Group LLC.
View insider buying and selling activity for iBio.

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.58.

How big of a company is iBio?

iBio has a market capitalization of $287.73 million. iBio employs 43 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.

This page was last updated on 12/2/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.